HLN.L

Haleon plc
Haleon PLC - Director/PDMR Shareholding
19th December 2024, 15:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8157Q
Haleon PLC
19 December 2024
 

Icon Description automatically generated

 

​Haleon plc: Director/PDMR Shareholding 

​ 

19 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

 

1  

 

Details of the person discharging managerial responsibilities / person closely associated  

 

a)  

 

Name  

 

Adrian Morris

2  

 

Reason for the notification  

 

a)  

 

Position/status  

 

 

General Counsel - PDMR

b)  

 

Initial notification /Amendment  

 

Initial Notification 

3  

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

 

a)  

 

Name  

 

Haleon plc 

b)  

 

LEI  

 

549300PSB3WWEODCUP19 

4  

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)  

 

Description of the financial instrument, type of instrument  

Ordinary Shares of £0.01 each

 



Identification code  

GB00BMX86B70

 



b)  

 

Nature of the transaction  

 

 

Grant of a 3-year option over Ordinary Shares under the 2024 Haleon Share Save Plan which will first become exercisable 1 February 2028.

 

c)  

 

Price(s) and volume(s)  







Price(s) 

Volume(s) 




£3.00

6,150







d)  

 

Aggregated information  




- Aggregated volume 




- Price 




e)  

 

Date of the transaction  

 

19 December 2024

f)  

 

Place of the transaction  

 

Outside a trading venue

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSBDDXUBDGSC]]>
TwitterFacebookLinkedIn